Treatment of Fabry’s Disease with the Pharmacologic Chaperone MigalastatDominique P. Germain, Raphael Schiffmann, Derralynn Hughes et al.|New England Journal of Medicine|2016Cited by 555
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus documentMarieke Biegstraaten, Carla E. M. Hollak, Derralynn Hughes et al.|Orphanet Journal of Rare Diseases|2015Cited by 345
2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central HypothyroidismLuca Persani, A S Paul van Trotsenburg, Georg Brabant et al.|European Thyroid Journal|2018Cited by 212
Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia:a systematic review and individual-participant data meta-analysisFreddy J.K. Toloza, Spyridoula Maraka, Arash Derakhshan et al.|University of Oulu Repository (University of Oulu)|2022Cited by 132
Alemtuzumab-induced thyroid disease: A Danish cohort studyJuliana Frohnert Hansen, Ulla Feldt‐Rasmussen, Melinda Magyari et al.|Multiple Sclerosis and Related Disorders|2024Cited by 5